Voyager names Robin Swartz president. Voyager Therapeutics stock costs EUR 1.59

Published on 10/27/2026 at 14:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Two Alzheimer programs will feature posters on November 16, 2026. Voyager Therapeutics stock costs EUR 1.59 at Lang & Schwarz on October 27, 2026.

Clinical milestones take shape

Voyager announced two Alzheimer disease poster presentations on October 27, 2026.
Second-quarter 2026 revenue was USD 3.17 million and net loss was USD 24.47 million.
Voyager Therapeutics stock trades at EUR 1.59 at 2:02 p.m. CEST at Lang & Schwarz on October 27, 2026.
The poster sessions are scheduled for November 16, 2026, while initial VY1706 safety data are expected in the first quarter of 2027.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (ISIN US92915B1061) was trading at EUR 1.59 at Lang & Schwarz on October 27, 2026, at 2:02 p.m. CEST. The company announced two Alzheimer disease poster presentations for its VY1706 gene therapy and VY7523 antibody, according to Morningstar on October 27, 2026.

Two posters mark the latest step

The presentations are scheduled for the Clinical Trials on Alzheimer's Disease conference in Boston. VY1706 is designed to lower tau production in the brain, while VY7523 is a clinical-stage monoclonal antibody directed at the C-terminal region of tau, the release said.

Three milestones frame the story

On August 6, 2026, Voyager reported second-quarter revenue of USD 3.17 million and a net loss of USD 24.47 million. MarketBeat reported the quarter's revenue and a USD 0.40 loss per share. On October 21, 2026, the company appointed Robin Swartz as president, according to GlobeNewswire.

What comes next for the pipeline?

The poster sessions begin on November 16, 2026, giving Voyager a near-term venue to present early clinical information. The company also expects initial acute safety data from VY1706 in the first quarter of 2027, pending enrollment, and plans for Swartz to succeed Alfred Sandrock as CEO after that milestone, according to Voyager Therapeutics.

Stock quote and next dates

Voyager remains a clinical-stage biotechnology company focused on neurological diseases, with programs spanning Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Friedreich's ataxia. Voyager Therapeutics was trading at EUR 1.59 at Lang & Schwarz on October 27, 2026, at 2:02 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.